3 assets in Hepatitis C Induced Liver Cirrhosis

Therapeutic assets addressing Hepatitis C Induced Liver Cirrhosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carvedilol Hepatitis C Induced Liver Cirrhosis	Tianjin Second People's Hospital	P3	B (60)
Umbellatine Hepatitis C Induced Liver Cirrhosis	Tianjin Second People's Hospital	P3	B (60)
Rosuvastatin Hepatitis C Induced Liver Cirrhosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P2	CCC (53)